Zomedica Corp.
$0.12 N/A +0.49% 2.1M
Advancing animal health and veterinarian success
Company Overview
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $91 million cash, cash equivalents, and available-for-sale securities as of March 31, 2024, Zomedica is well-positioned to fund both organic growth and acquisitions. The Company’s portfolio includes innovative products that emphasize both patient and practice health, including:
Diagnostics and Therapeutic Devices:
- TRUFORMA® - In-clinic diagnostics with canine and feline assays
- TRUVIEW® - Innovative digital imaging technologies
- VetGuardian® - Wireless remote monitoring of vital signs
Therapeutic Devices:
- PulseVet® - Shock wave therapy in equine and small animal market
- Assisi® tPEMF® - Targeted pulsed electromagnetic field therapy
Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care.
Value Proposition
Zomedica’s rapidly increasing revenues and attractive gross margins offer a clear pathway to profitability. Successful acquisitions and collaborations provide a blueprint for continued organic growth and product expansion. With a product line-up designed to address the needs of both companion animals and the veterinarians they rely upon and an animal health market that continues to exponentially grow, Zomedica finds itself primed to capitalize on a substantial amount of market opportunities. Having accelerated its commercial launch cadence, Zomedica continues to address the unmet needs of the customers and the market it serves. With double-digit revenue growth and strong margins, combined with a decreasing operating cash burn, a strong balance sheet (incl. $91 million in liquidity with no debt), and profitability on the horizon, Zomedica is well positioned as a very compelling opportunity for fast-acting investors.
Investor Presentation
Investment Highlights
-
Substantial growth
- 2022 revenue of $18.9 million, up 361% from 2021
- 2023 revenue of $25.2 million, up 33% YoY
- 2024 revenue guidance: $31 million to $35 million, up 40% over 2023 revenue
- Historic margins of ~70%
-
Solid financial position
- Cash, cash equivalents, and available-for-sale securities at $90.9 million at Mar. 31, 2024
- Quarterly operating burn of ~$3 million
- No debt
-
Growing portfolio
- Therapeutic devices segment revenues up 28% YoY in 2023
- Diagnostic segment revenues up 252% YoY in 2023
-
Growing markets
- Animal health market estimated to reach $88.6 billion by 2028
- Companion animal diagnostic market forecasted to reach $12.6 billion by 2036
- Product portfolio represents a $2.5 billion annual market opportunity in US alone
- 23 million pets added during pandemic
Sign Up For ZOM Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Zomedica (ZOM) is a client of RedChip Companies, Inc. ZOM agreed to pay RedChip Companies, Inc. a $9,500 monthly cash fee, beginning in January 2024, for six months of RedChip investor awareness services. ZOM also agreed to pay RedChip a one-time $100,000 fee for a national TV ad campaigns aired weekdays from November 16 to December 12, 2023 and April 26 to May 24, 2024.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.